Sign in
Taking peoplePhase 2

The dual orexin receptor antagonist daridorexant as an adjunct to improve buprenorphine maintenance therapy of opioid use disorder

Key facts

Who runs it
Linkopings Universitet
Where
Sweden7 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 2
People taking part
192 people, planned
Started
4 Apr 2025
Expected to end
31 Aug 2029
Type of study
Interventional
Record updated
7 September 2026

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Men and women aged 20 - 65 years
  • Meet criteria for moderate-to-severe OUD ”opioid dependence” according to ICD-10, confirmed using a checklist of DMS-5 criteria for OUD by a trained nurse or physician. Other, co-morbid substance use disorders will be evaluated by obtaining a history and carrying out a chart review; these will be confirmed using a checklist of DSM-criteria for the respective substance, and will be recorded, but will not influence eligibility except as specified below
  • ≥1 year duration of OUD
  • Prospective participants will be eligible if they are not in stable remission, or if, despite being in stable remission from opioid use, they continue to use other substances in a manner that indicates they stand to potentially benefit from participating
  • Both patients not enrolled in OMT at the time of screening, and those with ongoing OMT with transmucosal buprenorphine formulations at that time will be eligible. Patients not currently enrolled in OMT will first be stabilized on transmucosal buprenorphine according to clinical routine
  • Able to speak and read Swedish
  • Willing to provide informed consent

Who cannot take part

  • Patients with concomitant use of strong CYP3A4 inhibitors (see Appendix 1 of protocol)
  • Patients with any serious psychiatric condition unless stable under treatment
  • Patients with any other condition or circumstances that, in the assessment of the investigator, lead to participation in the study not being in the best interest of the patient
  • Patients with severe respiratory insufficiency
  • Patients with any other serious medical condition, unless stable under treatment
  • Patients already in OMT with a depot formulation of buprenorphine, or who have been in OMT with a depot formulation of buprenorphine within the past 12 months
  • Patients enrolled in OMT with methadone
  • Patients with a diagnosis of narcolepsy
  • Women who are pregnant or plan on becoming pregnant, or who are nursing
  • Women of child-bearing potential will have to agree to practice reliable contraception (see Appendix 2 of protocol), or document that they intend to abstain from sexual intercourse

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

This trial is currently available in Sweden.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate whether daridorexant can reduce illicit substance use compared compared to placebo, when provided as an adjuntive treatment to OUD patients maintained on depot buprenorphine.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Criteria questions
Built from 2024-517482-16-00, who can take part
Record updated
7 September 2026